M. Lamba

587 total citations
17 papers, 356 citations indexed

About

M. Lamba is a scholar working on Molecular Biology, Oncology and Rheumatology. According to data from OpenAlex, M. Lamba has authored 17 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 6 papers in Oncology and 6 papers in Rheumatology. Recurrent topics in M. Lamba's work include Rheumatoid Arthritis Research and Therapies (6 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Histone Deacetylase Inhibitors Research (3 papers). M. Lamba is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (6 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Histone Deacetylase Inhibitors Research (3 papers). M. Lamba collaborates with scholars based in United States, Spain and United Kingdom. M. Lamba's co-authors include Chantal Bolduc, Sairah Khan, Shu-Ping Lan, Robert Bissonnette, W.C. Ports, Kim Papp, S. Krishnaswami, Michael A. Tortorici, Nervin Lawendy and Ellen Filvaroff and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Annals of the Rheumatic Diseases.

In The Last Decade

M. Lamba

17 papers receiving 346 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Lamba United States 8 138 100 92 89 76 17 356
Miguel Nogueira Portugal 9 212 1.5× 61 0.6× 109 1.2× 80 0.9× 32 0.4× 21 361
Keith Kerkof United States 7 191 1.4× 55 0.6× 93 1.0× 88 1.0× 163 2.1× 7 427
Caterina Baldi Italy 10 100 0.7× 158 1.6× 21 0.2× 42 0.5× 45 0.6× 52 423
Nikolay Delev United States 9 244 1.8× 295 3.0× 27 0.3× 71 0.8× 101 1.3× 24 409
Ralph Lippe Germany 14 268 1.9× 279 2.8× 37 0.4× 69 0.8× 153 2.0× 26 469
Dorota Cieślak Poland 6 261 1.9× 337 3.4× 48 0.5× 68 0.8× 191 2.5× 9 472
Caylib Durand Canada 9 158 1.1× 41 0.4× 20 0.2× 43 0.5× 55 0.7× 15 328
Elyssa Ott United States 9 199 1.4× 54 0.5× 71 0.8× 85 1.0× 28 0.4× 14 491

Countries citing papers authored by M. Lamba

Since Specialization
Citations

This map shows the geographic impact of M. Lamba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Lamba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Lamba more than expected).

Fields of papers citing papers by M. Lamba

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Lamba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Lamba. The network helps show where M. Lamba may publish in the future.

Co-authorship network of co-authors of M. Lamba

This figure shows the co-authorship network connecting the top 25 collaborators of M. Lamba. A scholar is included among the top collaborators of M. Lamba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Lamba. M. Lamba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Gronholm, Petra C., Sarah Kline, M. Lamba, et al.. (2024). Exploring perspectives of stigma and discrimination among people with lived experience of mental health conditions: a co-produced qualitative study. EClinicalMedicine. 70. 102509–102509. 4 indexed citations
2.
Hollebecque, Antoine, Johann S. de Bono, Stefania Salvagni, et al.. (2021). 7O Updated results from phase I study of CC-90011 in patients (pts) with solid tumours (STs), including neuroendocrine neoplasms (NENs), and relapsed/refractory non-Hodgkin lymphoma (R/R NHL). Annals of Oncology. 32. S4–S4. 1 indexed citations
3.
4.
Hollebecque, Antoine, Johann S. de Bono, Stefania Salvagni, et al.. (2020). 18O CC-90011 in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study. Annals of Oncology. 31. S6–S6. 3 indexed citations
5.
Paz‐Ares, Luis, Óscar Juan, Enric Carcereny, et al.. (2020). 559P Phase Ib study of CC-90011 plus etoposide and cisplatin (EP) in patients with first-line extensive-stage (ES) small cell lung cancer (SCLC). Annals of Oncology. 31. S482–S483. 2 indexed citations
6.
Moreno, Víctor, Juan Manuel Sepúlveda-Sánchez, María Vieito, et al.. (2020). Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma. Annals of Oncology. 31(6). 780–788. 50 indexed citations
7.
Hollebecque, Antoine, Johann S. de Bono, Ruth Plummer, et al.. (2019). Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL). Annals of Oncology. 30. i4–i4. 11 indexed citations
8.
Vollenhoven, Ronald van, Ernest Choy, Irina Lazariciu, et al.. (2016). THU0199 Tofacitinib, An Oral Janus Kinase Inhibitor, in The Treatment of Rheumatoid Arthritis: Changes in Lymphocytes and Lymphocyte Subset Counts and Reversibility after Up To 8 Years of Tofacitinib Treatment. Annals of the Rheumatic Diseases. 75. 258–258. 8 indexed citations
9.
Lamba, M., D.E. Furst, Ara Dikranian, et al.. (2016). Model‐Informed Development and Registration of a Once‐Daily Regimen of Extended‐Release Tofacitinib. Clinical Pharmacology & Therapeutics. 101(6). 745–753. 31 indexed citations
10.
Vincenti, Flavio, Stéphan Busque, Philip J. O’Connell, et al.. (2015). Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients. American Journal of Transplantation. 15(6). 1644–1653. 45 indexed citations
11.
Vollenhoven, Ronald van, Yoshiya Tanaka, M. Lamba, et al.. (2015). THU0178 Relationship Between NK Cell Count and Important Safety Events in Rheumatoid Arthritis Patients Treated with Tofacitinib. Annals of the Rheumatic Diseases. 74. 258–259. 12 indexed citations
12.
Kawabata, Thomas T., Wichard Vogel, Richard J. Riese, et al.. (2014). AB0474 Changes in T and B Lymphocyte Subsets with Tofacitinib do not Translate from Nonclinical Species to Humans. Annals of the Rheumatic Diseases. 73. 964–965. 1 indexed citations
13.
Lamba, M., Tracey Fletcher, Christine Alvey, et al.. (2014). THU0143 Pharmacokinetics, Bioavailability and Safety of A Modified Release Once Daily Formulation of Tofacitinib in Healthy Volunteers. Annals of the Rheumatic Diseases. 73. 228–228. 2 indexed citations
14.
Ports, W.C., Sairah Khan, Shu-Ping Lan, et al.. (2013). A randomized phase 2a efficacy and safety trial of the topical J anus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. British Journal of Dermatology. 169(1). 137–145. 163 indexed citations
15.
Farmer, James, et al.. (2013). Salivary Gland Lymphoproliferative Disorders: A Canadian Tertiary Center Experience. Head and Neck Pathology. 7(4). 381–388. 12 indexed citations
16.
Vollenhoven, Ronald van, Richard J. Riese, S. Krishnaswami, et al.. (2013). THU0252 Relationship between Lymphocyte Count and Risk of Infection in Rheumatoid Arthritis Patients Treated with Tofacitinib. Annals of the Rheumatic Diseases. 72. A250–A251. 7 indexed citations
17.
Lamba, M., Geetashree Mukherjee, Kamal S. Saini, et al.. (2007). Clinico-pathologic pattern of gastrointestinal stromal tumors (GIST) in southern India: A single-institution experience. Journal of Clinical Oncology. 25(18_suppl). 20531–20531. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Miguel Nogueira Breakdown of academic impact, for papers by Keith Kerkof Breakdown of academic impact, for papers by Caterina Baldi Breakdown of academic impact, for papers by Nikolay Delev Breakdown of academic impact, for papers by Ralph Lippe Breakdown of academic impact, for papers by Dorota Cieślak Breakdown of academic impact, for papers by Caylib Durand Breakdown of academic impact, for papers by Elyssa Ott
Rankless by CCL
2026